antigen in a subject comprising administering an adjuvant composition comprising an pyrrolizidine alkaloid not including the compounds of Group I.

III. Claim 61 (in part), drawn to a method of polarizing an immune response to an antigen in a subject comprising administering an adjuvant composition comprising an alkaloid compound not including the compounds of Groups I-II.

Applicants hereby elect Group I (claims 43-60 and 61-62 (in part)). The restriction requirement states that for any of Groups I-III, Applicant is required to elect for each of (i)-(ii), and, if Group I is elected, Applicant must also elect for each of (iii)-(iv):

(i) A single disclosed Th1-activating alkaloid compound specie within the scope of the general formula of claim 43, or within the scope of one of the classes of compounds recited in claims 61-62; elect a single compound from the compound recited in claims 59-60, or from those disclosed in the specification;

(ii) each antigen specie of the vaccine administered to a single subject; elect each antigen specie administered from the antigen species recited in claims 51-52, or disclosed in the specification; and identify which of genera recited in claims 49-50 and 53-54 read on the elected species

(iii) each additional component specie, if any, administered to the subject; elect each component specie administered, from the species recited in claims 47-48;

(iv) a single administration route specie, elected from the species recited in claims 57-58.

Because Group I is elected, Applicant also makes the following four elections as required by the Examiner:

(i) – The Th1-activating alkaloid species elected is "3,7-diepi-casuarine" shown below (also shown on page 10 of the published application):



3,7-diepi-casuarine

The restriction requirement also required Applicant to identify the claims readable on the elected species, those claims are: claims 43-60 and 61-62 (in part)

(ii) – Applicant elects "protein(s) or peptide(s)" and "viral particles" as antigen species. The restriction requirement also required Applicant to identify the genera in claims 49-50 and 53-54 that read on the elected species, Applicant submits that each of the genera listed in claims 49-50 and 53-54 read on the elected species.

(iii) – Applicant elects "a type 2 adjuvant (such as Alum and/or MF59)" as an additional component species.

(iv) – Finally, Applicant elects "subcutaneous injection" as the administration route species.

The Examiner is invited to contact Applicants' agent at the telephone number given below, if any further questions arise in connection with this Application.

Respectfully submitted,

Brian Reese

_____

Brian E. Reese
Attorney for Applicants
Reg. No. 64,538

Dated: May 27, 2010
HESLIN ROTHENBERG FARLEY & MESITI P.C.
5 Columbia Circle
Albany, New York 12203
Telephone: (518) 452-5600 Facsimile: (518) 452-5579